Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy

Allan Lipton, Kim Leitzel, Suhail M. Ali, Laurence Demers, Harold Harvey, Hilary A. Chaudri-Ross, Dean Evans, Raquel Lang, Wolfgang Hackl, Peter Hamer, Walter Carney

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

BACKGROUND. Prolonged exposure of breast carcinoma cells in vitro to tamoxifen results in tamoxifen resistance. Tamoxifen-resistant cells express increased HER-2/neu mRNA and protein. The objective of this study was to determine whether patients with metastatic or locally advanced breast carcinoma who have negative serum HER-2/neu status at the initiation of first-line hormone therapy with letrozole or tamoxifen convert to positive serum HER-2/neu status at the time of disease progression and to determine whether serum HER-2/neu conversion to positive status is associated with response to therapy and overall survival. METHODS. Serum samples were obtained at baseline and at the time of disease progression from 240 patients who initially had negative serum HER-2/neu status (< 15 ng/mL). A manual microtiter, enzyme-linked immunosorbent assay that was specific for the extracellular domain of the HER-2/neu (c-erbB-2) oncoprotein product was used to quantitate serum levels. RESULTS. Among 240 patients, 61 patients (26%) converted from serum HER-2/neu negative to positive (> 15 ng/mL) at the time of disease progression. Thirty-two of 129 patients (25%) who were treated with tamoxifen and 29 of 111 patients (26%) who were treated with letrozole became converted to positive serum HER-2/neu status at the time of disease progression. The response rate and the time to disease progression on first-line hormone therapy were not affected by serum HER-2/neu conversion. The survival of patients who converted to positive serum HER-2/neu status was significantly shorter compared with the survival of patients who remained negative for serum HER-2/neu. A multivariate analysis revealed that conversion to positive serum HER-2/neu status was an independent prognostic variable for survival. CONCLUSIONS. Conversion to positive serum HER-2/neu status occurred in approximately 25% of patients who received first-line hormone therapy. Conversion to serum HER-2/neu-positive status occurred with equal frequency in antiestrogen and aromatase-inhibitor therapy. The current results showed that serum conversion to HER-2/neu-positive status was an independent risk factor for decreased survival in patients with breast carcinoma.

Original languageEnglish (US)
Pages (from-to)257-263
Number of pages7
JournalCancer
Volume104
Issue number2
DOIs
StatePublished - Jul 15 2005

Fingerprint

Disease Progression
Hormones
Breast Neoplasms
Serum
Tamoxifen
letrozole
Therapeutics
Survival
Aromatase Inhibitors
Estrogen Receptor Modulators
Multivariate Analysis
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lipton, Allan ; Leitzel, Kim ; Ali, Suhail M. ; Demers, Laurence ; Harvey, Harold ; Chaudri-Ross, Hilary A. ; Evans, Dean ; Lang, Raquel ; Hackl, Wolfgang ; Hamer, Peter ; Carney, Walter. / Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. In: Cancer. 2005 ; Vol. 104, No. 2. pp. 257-263.
@article{0f69b3f1c2804f87ad32addfa92ea21a,
title = "Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy",
abstract = "BACKGROUND. Prolonged exposure of breast carcinoma cells in vitro to tamoxifen results in tamoxifen resistance. Tamoxifen-resistant cells express increased HER-2/neu mRNA and protein. The objective of this study was to determine whether patients with metastatic or locally advanced breast carcinoma who have negative serum HER-2/neu status at the initiation of first-line hormone therapy with letrozole or tamoxifen convert to positive serum HER-2/neu status at the time of disease progression and to determine whether serum HER-2/neu conversion to positive status is associated with response to therapy and overall survival. METHODS. Serum samples were obtained at baseline and at the time of disease progression from 240 patients who initially had negative serum HER-2/neu status (< 15 ng/mL). A manual microtiter, enzyme-linked immunosorbent assay that was specific for the extracellular domain of the HER-2/neu (c-erbB-2) oncoprotein product was used to quantitate serum levels. RESULTS. Among 240 patients, 61 patients (26{\%}) converted from serum HER-2/neu negative to positive (> 15 ng/mL) at the time of disease progression. Thirty-two of 129 patients (25{\%}) who were treated with tamoxifen and 29 of 111 patients (26{\%}) who were treated with letrozole became converted to positive serum HER-2/neu status at the time of disease progression. The response rate and the time to disease progression on first-line hormone therapy were not affected by serum HER-2/neu conversion. The survival of patients who converted to positive serum HER-2/neu status was significantly shorter compared with the survival of patients who remained negative for serum HER-2/neu. A multivariate analysis revealed that conversion to positive serum HER-2/neu status was an independent prognostic variable for survival. CONCLUSIONS. Conversion to positive serum HER-2/neu status occurred in approximately 25{\%} of patients who received first-line hormone therapy. Conversion to serum HER-2/neu-positive status occurred with equal frequency in antiestrogen and aromatase-inhibitor therapy. The current results showed that serum conversion to HER-2/neu-positive status was an independent risk factor for decreased survival in patients with breast carcinoma.",
author = "Allan Lipton and Kim Leitzel and Ali, {Suhail M.} and Laurence Demers and Harold Harvey and Chaudri-Ross, {Hilary A.} and Dean Evans and Raquel Lang and Wolfgang Hackl and Peter Hamer and Walter Carney",
year = "2005",
month = "7",
day = "15",
doi = "10.1002/cncr.21202",
language = "English (US)",
volume = "104",
pages = "257--263",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

Lipton, A, Leitzel, K, Ali, SM, Demers, L, Harvey, H, Chaudri-Ross, HA, Evans, D, Lang, R, Hackl, W, Hamer, P & Carney, W 2005, 'Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy', Cancer, vol. 104, no. 2, pp. 257-263. https://doi.org/10.1002/cncr.21202

Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. / Lipton, Allan; Leitzel, Kim; Ali, Suhail M.; Demers, Laurence; Harvey, Harold; Chaudri-Ross, Hilary A.; Evans, Dean; Lang, Raquel; Hackl, Wolfgang; Hamer, Peter; Carney, Walter.

In: Cancer, Vol. 104, No. 2, 15.07.2005, p. 257-263.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy

AU - Lipton, Allan

AU - Leitzel, Kim

AU - Ali, Suhail M.

AU - Demers, Laurence

AU - Harvey, Harold

AU - Chaudri-Ross, Hilary A.

AU - Evans, Dean

AU - Lang, Raquel

AU - Hackl, Wolfgang

AU - Hamer, Peter

AU - Carney, Walter

PY - 2005/7/15

Y1 - 2005/7/15

N2 - BACKGROUND. Prolonged exposure of breast carcinoma cells in vitro to tamoxifen results in tamoxifen resistance. Tamoxifen-resistant cells express increased HER-2/neu mRNA and protein. The objective of this study was to determine whether patients with metastatic or locally advanced breast carcinoma who have negative serum HER-2/neu status at the initiation of first-line hormone therapy with letrozole or tamoxifen convert to positive serum HER-2/neu status at the time of disease progression and to determine whether serum HER-2/neu conversion to positive status is associated with response to therapy and overall survival. METHODS. Serum samples were obtained at baseline and at the time of disease progression from 240 patients who initially had negative serum HER-2/neu status (< 15 ng/mL). A manual microtiter, enzyme-linked immunosorbent assay that was specific for the extracellular domain of the HER-2/neu (c-erbB-2) oncoprotein product was used to quantitate serum levels. RESULTS. Among 240 patients, 61 patients (26%) converted from serum HER-2/neu negative to positive (> 15 ng/mL) at the time of disease progression. Thirty-two of 129 patients (25%) who were treated with tamoxifen and 29 of 111 patients (26%) who were treated with letrozole became converted to positive serum HER-2/neu status at the time of disease progression. The response rate and the time to disease progression on first-line hormone therapy were not affected by serum HER-2/neu conversion. The survival of patients who converted to positive serum HER-2/neu status was significantly shorter compared with the survival of patients who remained negative for serum HER-2/neu. A multivariate analysis revealed that conversion to positive serum HER-2/neu status was an independent prognostic variable for survival. CONCLUSIONS. Conversion to positive serum HER-2/neu status occurred in approximately 25% of patients who received first-line hormone therapy. Conversion to serum HER-2/neu-positive status occurred with equal frequency in antiestrogen and aromatase-inhibitor therapy. The current results showed that serum conversion to HER-2/neu-positive status was an independent risk factor for decreased survival in patients with breast carcinoma.

AB - BACKGROUND. Prolonged exposure of breast carcinoma cells in vitro to tamoxifen results in tamoxifen resistance. Tamoxifen-resistant cells express increased HER-2/neu mRNA and protein. The objective of this study was to determine whether patients with metastatic or locally advanced breast carcinoma who have negative serum HER-2/neu status at the initiation of first-line hormone therapy with letrozole or tamoxifen convert to positive serum HER-2/neu status at the time of disease progression and to determine whether serum HER-2/neu conversion to positive status is associated with response to therapy and overall survival. METHODS. Serum samples were obtained at baseline and at the time of disease progression from 240 patients who initially had negative serum HER-2/neu status (< 15 ng/mL). A manual microtiter, enzyme-linked immunosorbent assay that was specific for the extracellular domain of the HER-2/neu (c-erbB-2) oncoprotein product was used to quantitate serum levels. RESULTS. Among 240 patients, 61 patients (26%) converted from serum HER-2/neu negative to positive (> 15 ng/mL) at the time of disease progression. Thirty-two of 129 patients (25%) who were treated with tamoxifen and 29 of 111 patients (26%) who were treated with letrozole became converted to positive serum HER-2/neu status at the time of disease progression. The response rate and the time to disease progression on first-line hormone therapy were not affected by serum HER-2/neu conversion. The survival of patients who converted to positive serum HER-2/neu status was significantly shorter compared with the survival of patients who remained negative for serum HER-2/neu. A multivariate analysis revealed that conversion to positive serum HER-2/neu status was an independent prognostic variable for survival. CONCLUSIONS. Conversion to positive serum HER-2/neu status occurred in approximately 25% of patients who received first-line hormone therapy. Conversion to serum HER-2/neu-positive status occurred with equal frequency in antiestrogen and aromatase-inhibitor therapy. The current results showed that serum conversion to HER-2/neu-positive status was an independent risk factor for decreased survival in patients with breast carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=22244446128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22244446128&partnerID=8YFLogxK

U2 - 10.1002/cncr.21202

DO - 10.1002/cncr.21202

M3 - Article

C2 - 15952182

AN - SCOPUS:22244446128

VL - 104

SP - 257

EP - 263

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -